Alaunos Therapeutics, Inc. (TCRT)Healthcare | Biotechnology | Houston, United States | NasdaqCM
2.92 USD
+0.09
(3.180%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.96 +0.04 (1.370%) ⇧ (April 17, 2026, 7:37 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:45 p.m. EDT
High-risk speculative play with deteriorating fundamentals; negative revenue growth and massive valuation multiples (P/S >1300x) offer no long-term safety margin, while the model predicts only marginal -3.4% upside within a month due to low heteroscedasticity and high volatility. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.081883 |
| AutoETS | 0.081884 |
| AutoTheta | 0.083913 |
| MSTL | 0.097568 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.725 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.003 |
| Market Cap | 6,944,502 |
| Forward P/E | -4.87 |
| Beta | -1.13 |
| Previous Name | ZIOPHARM Oncology, Inc. |
| Website | https://www.alaunos.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.24255323 |
| Address1 | 2,617 Bissonnet Street |
| Address2 | Suite 233 |
| All Time High | 2,400.0 |
| All Time Low | 1.31 |
| Ask | 3.38 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 15,670 |
| Average Daily Volume3 Month | 16,095 |
| Average Volume | 16,095 |
| Average Volume10Days | 15,670 |
| Beta | -1.132 |
| Bid | 2.41 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 1.271 |
| City | Houston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.92 |
| Current Ratio | 2.445 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.92 |
| Day Low | 2.77 |
| Display Name | Alaunos Therapeutics |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -4,218,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.318 |
| Enterprise To Revenue | 1,111.9 |
| Enterprise Value | 5,559,499 |
| Eps Forward | -0.6 |
| Eps Trailing Twelve Months | -2.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0 |
| Fifty Day Average Change | -0.07999992 |
| Fifty Day Average Change Percent | -0.026666641 |
| Fifty Two Week Change Percent | 24.255323 |
| Fifty Two Week High | 6.2 |
| Fifty Two Week High Change | -3.2799997 |
| Fifty Two Week High Change Percent | -0.52903223 |
| Fifty Two Week Low | 1.67 |
| Fifty Two Week Low Change | 1.2500001 |
| Fifty Two Week Low Change Percent | 0.7485031 |
| Fifty Two Week Range | 1.67 - 6.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,124,890,200,000 |
| Float Shares | 1,886,716 |
| Forward Eps | -0.6 |
| Forward P E | -4.866667 |
| Free Cashflow | -753,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -1,358,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04103 |
| Held Percent Institutions | 0.05973 |
| Implied Shares Outstanding | 2,378,254 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.ziopharm.com/index.cfm |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,721,260,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas. |
| Long Name | Alaunos Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 6,944,502 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_11686323 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -4,282,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,706,673 |
| Open | 2.8855 |
| Operating Cashflow | -2,869,000 |
| Operating Margins | -302.3333 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.58 |
| Phone | 346 355 4099 |
| Post Market Change | 0.03999996 |
| Post Market Change Percent | 1.3698617 |
| Post Market Price | 2.96 |
| Post Market Time | 1,776,469,051 |
| Prev Name | ZIOPHARM Oncology, Inc. |
| Previous Close | 2.83 |
| Price Hint | 4 |
| Price To Book | 2.2974036 |
| Price To Sales Trailing12 Months | 1,388.9004 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.707 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0900002 |
| Regular Market Change Percent | 3.18022 |
| Regular Market Day High | 2.92 |
| Regular Market Day Low | 2.77 |
| Regular Market Day Range | 2.77 - 2.92 |
| Regular Market Open | 2.8855 |
| Regular Market Previous Close | 2.83 |
| Regular Market Price | 2.92 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 11,262 |
| Return On Assets | -0.92313004 |
| Return On Equity | -1.9810201 |
| Revenue Growth | -0.25 |
| Revenue Per Share | 0.003 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 2,378,253 |
| Shares Percent Shares Out | 0.006 |
| Shares Short | 14,162 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 34,253 |
| Short Name | Alaunos Therapeutics, Inc. |
| Short Percent Of Float | 0.0062 |
| Short Ratio | 0.76 |
| Source Interval | 15 |
| State | TX |
| Symbol | TCRT |
| Total Cash | 1,385,000 |
| Total Cash Per Share | 0.582 |
| Total Debt | 0 |
| Total Revenue | 5,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.00985 |
| Two Hundred Day Average Change | -0.08984995 |
| Two Hundred Day Average Change Percent | -0.02985197 |
| Type Disp | Equity |
| Volume | 11,262 |
| Website | https://www.alaunos.com |
| Zip | 77,005 |